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doi:10.1016/j.kjms.2011.05.007Abstract Arsenic is a well-known human carcinogen. It also impairs immune functions and
activation in many aspects. However, only a small portion of arsenic-exposed population
develops skin abnormalities, including Bowen’s disease and skin cancers. Differential immune
activation among the individuals might account for the different susceptibilities. In patients
with arsenic-induced Bowen’s disease, there is a selective CD4 T-cell apoptosis through tumor
necrosis factor-alpha pathway, decrease in macrophage differentiation and phagocytosis,
reduced Langerhans cell numbers and dendrites, altered regulatory T-cell distribution, and
other immune alterations. Several lines of evidence from mouse and fish studies also confirmed
the potent and multifaceted effects of arsenic in the immune system. The molecular bases of
immunosuppression by arsenic in lymphocytes may include chromosomal and DNA abnormali-
ties, decreased T-cell receptor activation, and the cellular status of oxidation and methyla-
tion. This article also reviews the causative and differential role of selective CD4 cell
apoptosis and the carcinogenesis of arsenic-induced Bowen’s disease.
Copyright ª 2011, Elsevier Taiwan LLC. All rights reserved.Introduction
Arsenic accumulation in the environment has been inten-
sified by human activities, such as fossil fuel combustion,
metal smelting and mining, and semiconductor and glass
industries [1]. Interestingly, only around 10% of the pop-
ulation exposed to arsenic develop skin abnormalities,t of Dermatology, Kaohsiung
Road, Kaohsiung 807, Taiwan.
.tw (H.-S. Yu).
vier Taiwan LLC. All rights reservincluding hyper-/hypopigmentations, arsenic keratosis,
Bowen’s disease, and invasive skin cancers. Among these
people exposed to arsenic, only up to 1% of the population
develops skin cancers. Personal genetic variability, immune
system, and the interaction of both might differ, leading to
differential susceptibilities. Long-term arsenic exposure
results in impaired immunity in some susceptible individ-
uals. The decrease in contact hypersensitivity reaction is
the hallmark of decrease in cellular immunity and occurs in
patients with arsenic-induced Bowen’s disease. Bowen’s
disease, a skin carcinoma in situ, can occur in any area of
the skin. Clinically, arsenic-induced Bowen’s disease tendsed.
Immune dysregulation in arsenical skin cancers 397to be multifocal and distributed in sun-protected skin,
whereas classical Bowen’s disease tends to be solitary and
mainly located in sun-exposed skin. Histopathologically,
there is no difference between arsenic-induced and clas-
sical Bowen’s disease. There are full layers of epidermal
dysplasia, hyperkeratosis, acanthosis, individual dysker-
atosis, and cellular dysplasia. Arsenic, as an immunotoxin,
is also the therapeutic choice for acute promyelocytic
leukemia, a special form of hematological malignancy from
myelocyte series. This article reviews the impact of arsenic
on immune system as a whole and the interaction of
selective immune suppression and the occurrence of skin
cancers in arsenic-exposed patients.
Overview of immunity and tumor immunity
Immune system is vital to fight against foreign pathogens,
to clear endogenous tumor antigens, and to recognize self
and foreign identities. It functions like a military force in
the body to fight against different enemies in different
ways. Immunity confers sufficient biological defenses to
avoid infection, disease, or cancers. Immune system could
be classified as specific and nonspecific components
(Fig. 1). The nonspecific, or innate, components act either
as barriers or as passive eliminators of a wide range of
pathogens, irrespective of antigenic specificity. Other
specific or adaptive components are able to generate
pathogen-specific immunity each time they encounter new
pathogens. The innate immune response is activated as the
first line of defense of the host and is a prerequisite of
potentiating the adaptive immune responses. Another
classification of immune system depends on the participa-
tion of cellular immune component. Either innate or
adaptive immune system could be classified into cellular
or humoral immunity that indicates the involvement of
immune cells or the antibodies, respectively.
The host immune system clears tumor antigens either
through natural killer cells or the cytotoxic T cells (CD8þ)
with the help of helper T (CD4þ) cells. On the other hand,
tumors may evade host immune surveillance by secreting
anti-inflammatory mediators, such as transforming growth
factor-beta, or direct the development of regulatory T
cells. Without an intact or a functional immune system,
apparently, the opportunistic infection will occur. An
example of chronic immunosuppression is seen in patientsImmunity
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Figure 1. The functional components of immune system.
NK Z natural killer.with renal transplantation on immunosuppressive drugs.
These patients tend to have increased risk of developing
multiple skin cancers [2].Arsenic induces aberrant innate and adaptive
immune responses
Arsenic exposure in mice diminished the formation of
immunoglobulin M and immunoglobulin G, antigen-medi-
ated T-cell proliferation [3,4], and macrophage phagocy-
totic activity and their nitric oxide release capacity as
well [5]. It also decreased CD4þ cell numbers from spleen
and suppressed contact hypersensitivity responses [6]. Of
note, arsenic-treated mice demonstrated a significantly
decreased resistance to the B16F10 melanoma with
a sevenfold increase in tumor burden at a dose of 200 mg/
kg. Studies of rodents in assessing human arsenic toxicity
are limited in human implications because arsenics are
proved to be human Class IA carcinogen but not a carcin-
ogen in rodents. In fact, a high concentration of arsenic is
usually required to have significant biological effects on
rodents. Nonetheless, a breakthrough of the mouse study in
arsenic is by Waalkes’ group that has demonstrated the
transplacental carcinogenesis in mice [7,8]. Male C3H mice
exposed to arsenic in utero developed liver carcinoma and
adrenal cortical adenoma during adulthood. Prenatally
exposed female C3H offspring showed increases in ovarian
tumors, lung carcinoma, and proliferative lesions of the
uterus and oviduct. In addition, prenatal plus postnatal
arsenic exposure to the tumor promoter, 12-O-tetradeca-
noyl phorbol-13-acetate (TPA), in C3H mice produces excess
lung tumors in both sexes and liver tumors in females [7,8].
However, fetal arsenic exposure does not increase the risk
of skin cancers unless the strain had genomic susceptibility
(TgAC mice) and when TPA was also applied, implicating
stem cells as a target of arsenic in the fetal basis of skin
cancer in adulthood [9]. Although the immune status of
these offspring mice was not checked, the epidemiological
studies have declared that in utero arsenic exposure
impaired child thymic development and enhanced
morbidity, probably through immunosuppression [10].
Not only are the immune responses of rodents are
altered by arsenic but also the innate immune system was
suppressed in zebrafish [11]. Exposure to 2-ppb and 10-ppb
arsenic, both considered safe levels in drinking water,
resulted in a greater than 50-fold increase in viral load and
at least a 17-fold increase in bacterial load in embryos of
zebrafish. Declines of proinflammatory cytokines were
noticed, including tumor necrosis factor-alpha (TNF-alpha),
IL-1 beta, and interferon. The utilization of zebrafish in
arsenic toxicity has the advantages of short study time, in
vivo demonstration, and impact on embryonic develop-
ment. In a study from catfish, leukocyte counts from spleen
and total head kidney were reduced in catfish exposed to
42 mM arsenic, 1/50th of the toxic dose [12]. Of note,
bacterial phagocytosis was interfered with and the immune
status to Clarias batrachus was weakened. Thus, organ- and
cell-specific effects by arsenic are demonstrated in the
immune functions of catfish.
Monocytes and macrophages may also constitute
the major targets of arsenic. Differentiation between
398 C.-H. Lee et al.monocytes and macrophages in humans is impaired by
arsenic. Arsenic induced a rapid cell rounding, loss of
adhesion, and actin reorganization, mainly through Ras
homolog gene family member A-associated kinase pathway
[13]. Thus, human macrophages are also sensitive targets of
arsenic immunotoxicity.
Low concentrations (<5 mM) of arsenic tended to increase
the number of natural T-regulatory (nTreg) lymphocytes
from normal controls. However, in healthy subjects chroni-
cally exposed to arsenic, urinary arsenic levels are inversely
correlated with the number and function of nTreg lympho-
cytes. Rats exposed to arsenic also showed redistribution
of nTreg cells and increased the levels of nTreg cells in
spleen in experimental allergic encephalomyelitis model.
The results indicated that arsenic seems to have a complex
effect on nTreg cells [14].
Immunological biomarkers for arsenic
exposure in humans
Several biomarker studies have been performed to corre-
late arsenic exposure with human hazards. In these
studies, immune functions, T-cell responses, and cytokine/
chemokine dysregulation are revealed. Microarray
genome-wide analysis from US New Hampshire residents
revealed that overrepresentation of genes was involved
in defense response, immune function, cell growth,
apoptosis, cell cycle regulation, T-cell receptor (TCR)
signaling pathway, and diabetes [15]. Killer cell immuno-
globulin-like receptor and human major histocompatibility
complex, Class II, HLA-DQ alpha 1, and perforin are among
those with high correlations. Wu et al. [16], by DNA
microarray and enzyme-linked immunosorbent assay,
found that IL-1 beta, IL-6, CCL2, CXCL1, CXCL2, CD14,
matrix metalloproteinase 1 were upregulated in persons
with increased arsenic exposure. The association of CCL2
plasma protein level with blood arsenic remained signifi-
cant after adjustment for other risk factors of cardiovas-
cular diseases [16].
Molecular mechanisms of defective T-cell
activation and innate immunity by arsenic
in humans
Although tremendous efforts have been aimed at deter-
mining the defect of cell immunity, the studies that tackle
molecular mechanisms by which arsenic induces a decrease
in T-cell proliferation, activation, and macrophage differ-
entiation, and phagocytosis remains scanty. Arsenic
compounds at very low concentrations enhanced DNA
synthesis in phytohemagglutinin-stimulated proliferation of
human lymphocytes, whereas higher concentrations
inhibited DNA synthesis [17]. Arsenic induces aneuploidy
[18,19], sister chromatid changes [20e22], and other
chromosomal abnormalities [23] in lymphocytes. Ataxia
telangiectasia mutated status confers sensitivity to arsenic
cytotoxic effects through p53 [24]. Of note, among the
metabolites of arsenic, MMA(III) and DMA(III) are candidate
ultimate genotoxic forms of arsenic, and they are clas-
togens and not gene mutagens [25].Arsenic interferes with the signaling transduction
pathway of TCR activation by increasing basal and induced
phosphorylation of lymphocyte-specific protein tyrosine
kinase and Fyn (first kinases associated with TCR complex)
in spleen cells [26]. Metabolites of arsenic can also inter-
fere with cell division by means of tubulin disruption,
leading to aneuploidy [27]. A major cellular source of
methyl group, S-adenosyl-L-methionine, is able to reverse
micronucleus formation induced by sodium arsenite and
other cytoskeleton-disrupting agents in cultured human
lymphocytes [28].
In contrast to the scanty studies that aim at the
molecular mechanisms of arsenic on normal lymphocytes,
there are a bunch of studies investigating the molecular
mechanisms of arsenic-induced apoptosis in cells of
lymphomaeleukemia. Arsenic remains the drug of choice
for a special kind of acute myelocytic leukemia, acute
promyelocytic leukemia. Arsenic induces normalization
of differentiation of promyelocytes in acute promyelo-
cytic leukemia. Phosphoinositide 3-kinase/Akt inhibition
increases arsenic trioxide-induced apoptosis of acute pro-
myelocytic and T-cell leukemia [29]. Arsenic induces
apoptosis through activation of Bax in hematopoietic cells
[30]. Furthermore, arsenic trioxide (As) and interferon-
alpha synergize to induce cell cycle arrest and apoptosis
that is modulated by bcl-2, bax, p53, and NF-kappaB
[31,32]. Thus, the effects of arsenic on T-cell development
may act as a double-sided sword and appear to be cell
specific and concentration dependent.
Cell targets of immune system in
arsenic-induced skin cancers
In humans, several immune cells could be the targets of
arsenic. T cells are cells that have been studied exten-
sively. Phytohemagglutinin-induced T-cell proliferation is
impaired in T cells from patients with arsenic-induced
Bowen’s disease [33,34]. Indeed, there are dose-dependent
responses of T cells to arsenic. Lower concentrations of
arsenic (<1 mM) result in modest proliferations, whereas
higher concentrations of arsenic (>2 mM) lead to apoptosis
of T cells. Arsenic leads to preferentially CD4 cell apoptosis
through an autocrine TNF-alpha loop that accentuates
upregulation of TNF-alpha receptors on the surface and the
increased release of TNF-alpha [33,35]. Not only the
TNF-alpha loop is dysregulatedbut also the IL-2/IL-2R
T-cell activation loop is impaired. Production of soluble
IL-2 and expression of IL-2R on the T cells from patients
with arsenic-induced Bowen’s disease were significantly
reduced, reflecting the decreased thymidine uptake in
those T cells [36,37]. These results were confirmed in
arsenic-exposed children from central Mexico [38] and
adults in West Bengal [39], reemphasizing the impaired
T-cell activation by arsenic.
Those patients also had impaired delayed-type hyper-
sensitive response to 2,4-dinitrochlorobenzene. There were
quantitative loss in numbers and qualitative impairment
of dendrite formation in Langerhans cells located in the
arsenic-induced Bowen’s disease. It is evident that cell-
mediated immunity was depressed in patients with arsenic-
induced Bowen’s disease [36].
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pathogenesis of arsenic-induced Bowen’s
disease
Both GM-CSF and TGF-alpha were found in the epidermis
at clinically normal sites within 10 weeks after arsenic
treatment in vivo and also from arsenic-treated keratino-
cytes [40,41]. Injection of neutralizing antibodies to
GM-CSF after TPA application reduced the number of papil-
lomas in TgAC mice that are prone to develop papillomas
after arsenic exposure. These results suggested that arsenic
enhances development of skin neoplasias by the chronic
stimulation of keratinocyte-derived growth factors [40,41].
Although a clear link has been established for impaired T-
cell proliferation by arsenic, the causative role of impaired
T-cell activation and increased T-cell apoptosis with the
cutaneous tumorigenesis has been seldom discussed.
Patients with arsenic-induced Bowen’s disease (As-BD) have
lower percentage of peripheral CD4þ cells compared with
the control subjects; the CD4þ cells from As-BD patients
were less susceptible to arsenic-induced apoptosis because
of reduced tumor necrosis factor receptor 1 expression.
Systemically, the percentage of CD4þ cells was decreased in
the peripheral blood of As-BD patients. These residual CD4þ
cells were less susceptible to arsenic-induced apoptosis.
However, once infiltrated into the As-BD lesions, fas ligand
might mediate the selective CD4þ cell apoptosis from ker-
atinocytes (Fig. 2). This additional tumor-anti-immune
phenomenon present in the cutaneous environment
provides a reasonable explanation for the frequent occur-
rence of arsenical cancers in the skin [42].Figure 2. A scheme of selective CD4 cell apoptosis in the
pathogenesis of arsenic-induced Bowen’s disease. As-BD Z
arsenic-induced Bowen’s disease; sFasL Z soluble Fas ligand;
TNF-R1 Z tumor necrosis factor receptor 1.Discussions
With millions of population worldwide still exposed to
arsenic and the fact that arsenic is used to treat many
forms of cancers, the investigations of mechanisms and
effects of arsenic on immune system and tumor immunity,
in particular, are of paramount importance. The indolent
course of arsenic-induced skin cancer confers a good model
to study tumor immunity, particularly chemical immu-
nology, chemical carcinogenesis, and their interactions.
Lessons from previous studies tell us that depending on its
concentrations, arsenic exerts its modulatory effects on
immune cells in terms of their proliferation, apoptosis,
development, and differentiation. Through DNA damages,
chromosome abnormalities, and signal transduction of
survival and apotosis pathways, T cells, CD4þ cells, mono-
cytes, and macrophages are all affected by arsenic.
However, how those immune effects confer to arsenic
carcinogenesis and tumor progression is seldom addressed.
In our studies, we have shown that in arsenic-induced skin
cancer, circulatory CD4þ T cells undergo TNF-alpha-induced
apoptosis; once they infiltrate into skin with arsenic-
induced skin cancer, the infiltrated T cells undergo
FaseFasL-mediated apoptosis. Moreover, the question
remains to determine what extent of the immune changes
in Bowen’s disease is caused by the effects of arsenic
exposure rather than the consequences of the disease.
From these previous literatures, the question cannot be
easily answered. However, in the local skin, FaseFasL
interaction requires the participation of keratinocytes, the
cell origin for arsenic-induced Bowen’s disease. Perhaps,
the recent breakthrough mice models about arsenic carci-
nogenesis might give some clues of immune regulations in
the early development of arsenic cancers in the future.
Future research should incorporate comprehensive
approaches to address the arsenic susceptibility in humans,
the tumor immunity by arsenic, the prediction of immune
biomarkers to the development of internal cancers, and the
prognosis of arsenic-induced cancers. Many of those ques-
tions remain unanswered or largely unknown. The imple-
mentation of full-scale epidemiology studies, incorporating
molecular immunology, cellular immunology, molecular
epidemiology, high-throughput genetic and epigenetic
profiling, and dedications will address the pathophysiology
of adverse arsenic effects in humans, thus facilitating
individualized treatments and prevention measures for
exposed populations in the future. In chemical carcino-
genesis, the attribute of chemical immunology should be
always considered.Acknowledgments
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